While SNUC is still considered as a wastebasket entity, the progressive exclusion from this category of aggressive SNC with specific molecular identifiers such as ID-SNUC (21), SMARCA4-deficient carcinoma (22) and NUT carcinoma (23), together with the increasing use of neoadjuvant ChT-based regimens, has led to considerable improvement in SNUC-specific outcomes, particularly when treatment is based on chemoselection (20). This evidence concerns the gene SMARCA4 and carcinoma.